ALS is a progressive motor neuron disease with no effective treatment. The anti-excitotoxic
drug riluzole (100 mg/day) has been shown to decrease mortality and muscular …

The prognostic role of riluzole, enteral nutrition (EN), non-invasive ventilation (NIV) and
interdisciplinary care in ALS is still debated. A population based study has been performed …

Amyotrophic lateral sclerosis (ALS) has a 5-years mortality of 80%. Several treatment
modalities have been used to delay disease progression. The aim of the currrent study was …

Background Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis
(ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a …

Data from three observational databases have suggested that survival in patients with ALS
who take riluzole is far greater than that reported in randomized controlled studies. This …

Amyotrophic lateral sclerosis (ALS) still eludes all therapeutic efforts. In the past 10 years,
more than two dozen molecules have been studied, all with disappointing results. The …

Amyotrophic lateral sclerosis (ALS) is the commonest form of motor neuron disease and is a
fatal, degenerative, multisystem disorder affecting upper and/or lower motor neurons in the …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons
and other neuronal cells, leading to severe disability and eventually death from ventilatory …